Latest Personalized medicine Stories
PHILADELPHIA and REHOVOT, Israel, May 10, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of $625,000 as payment in full from the negotiated settlement announced on April 18, 2013 with Sanra Laboratories (Sanra) in connection with the Company's sale to Sanra of Parkway Clinical Laboratories (Parkway). On July 22, 2008, through Rosetta Genomics Inc., the Company purchased all of...
PHILADELPHIA and REHOVOT, Israel, May 7, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announces that the Company's miRview(®) suite of oncology diagnostic assays will be highlighted in an "Industry Expert Theater Presentation" at the American Society of Clinical Oncologists (ASCO) 2013 Annual Meeting taking place from May 31-June 4 at McCormick Place Convention Center in Chicago. The...
LEWISVILLE, Texas, May 1, 2013 /PRNewswire/ -- med fusion, Pathologists Bio-Medical Laboratories (PBM) and Theranostics Health will be introducing the first of Theranostics Health's TheraLink(TM) Assays for use in patients with malignant diseases at the upcoming American Society of Clinical Oncology (ASCO) Annual '13 Meeting, held in Chicago, IL from May 30,( )2013 through June 4, 2013. The TheraLink(TM) HER Family Assay for primary, recurrent and metastatic breast cancers provides a...
NEW YORK, April 30, 2013 /PRNewswire/ -- Diaceutics Limited, a leading personalized healthcare consultancy, and CAHG, a leading professional healthcare communications company, today announced a strategic partnership to develop marketing campaigns specific to personalized healthcare. This value-enhancing marketing service will enable pharmaceutical companies to comprehensively plan and execute global marketing campaigns relevant to targeted therapy and molecular diagnostics. (Logo:...
NEW YORK, April 29, 2013 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine, today announced that Kapil Dhingra, M.D., has been named chairman of Exosome Diagnostics Board of Directors. Dr. Dhingra, 52, has served as a member of Exosome's board of directors since March 2012. He has significant experience transforming oncology therapeutic and diagnostic development programs into products available...
- Corus CAD is the Only Clinically Validated Gene Expression Test for the Assessment of Obstructive Coronary Artery Disease - PALO ALTO, Calif., April 25, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, today announced it has entered into an agreement granting to Core Diagnostics India the exclusive right to market and sell CardioDx's Corus(®) CAD diagnostic test in India. Corus CAD is a noninvasive blood-based gene expression test...
LAUSANNE, Switzerland, April 24, 2013 /PRNewswire/ -- Oncotest GmbH and Debiopharm Group(TM) (Debiopharm) a Swiss-based global biopharmaceutical group, are pleased to announce the successful completion of the first biomarker projects at Oncotest. In a recent study, pharmacological data was generated with Debiopharm's investigational compound in Oncotest's 3D assay system for patient-derived xenografts and correlated with the extensive Oncotest's genomic and transcriptomic...
PHILADELPHIA and REHOVOT, Israel, April 18, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company has negotiated a settlement with Sanra Laboratories ("Sanra") in connection with the previous sale of Parkway Clinical Laboratories ("Parkway") by Rosetta Genomics to Sanra. Under the agreement, Sanra will undertake their best efforts to pay Rosetta Genomics $625,000, in...
Company Appoints Michael Duda as Vice President of Clinical Laboratory Operations and Jonathan Mayo as Vice President of Sales BETHLEHEM, Pa., April 18, 2013 /PRNewswire/ -- Saladax Biomedical, Inc., a privately held company developing and commercializing novel diagnostic assays to achieve the promise of personalized medicine for new and existing therapeutics, today announced it has appointed Jonathan Mayo as Vice President of Sales for the U.S. market and Michael Duda as Vice...
Researchers with the Institute of Urologic Oncology and the Department of Urology at UCLA have classified kidney cancer into several unique subtypes, a finding that will help physicians tailor treatment to individual patients and that moves cancer care one step closer to personalized medicine. The finding is the result of 10 years of UCLA researchers studying kidney cancers at the genetic and molecular levels, conducting chromosomal analyses in an effort to identify what mutations may be...
